Lyra Therapeutics, Inc. (LYRA)
NASDAQ·Healthcare·Biotechnology
$0.55
-58.33%
Mkt Cap $2.31M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 12, 2026 | $440.00K | $7.00K | -98.41% | -$2.59 | $8.00 | +408.88% | — | — |
| Q4 2025 Nov 12, 2025 | $205.67K | $25.00K | -87.84% | -$5.98 | -$3.38 | +43.48% | — | — |
| Q3 2025 Aug 12, 2025 | $154.25K | $183.00K | +18.64% | -$5.79 | -$5.51 | +4.84% | — | — |
| Q2 2025 May 6, 2025 | $161.33K | $183.00K | +13.43% | -$7.50 | -$6.00 | +20.00% | — | — |
| Q1 2025 Mar 13, 2025 | $206.00K | $209.00K | +1.46% | -$0.13 | -$0.16 | -23.08% | — | — |
| Q4 2024 Nov 12, 2024 | $204.80K | $195.00K | -4.79% | -$0.23 | -$0.18 | +21.74% | — | — |
| Q3 2024 Aug 14, 2024 | $350.00K | $598.00K | +70.86% | -$0.34 | -$0.29 | +14.71% | — | — |
| Q2 2024 Apr 30, 2024 | $344.92K | $532.00K | +54.24% | -$0.26 | -$0.35 | -34.62% | — | — |
| Q1 2024 Mar 21, 2024 | $388.80K | $146.00K | -62.45% | -$0.33 | -$0.22 | +33.33% | — | — |
| Q4 2023 Nov 7, 2023 | $390.00K | $544.00K | +39.49% | -$0.33 | -$0.27 | +18.18% | — | — |
| Q3 2023 Aug 8, 2023 | $140.00K | $458.00K | +227.14% | -$0.44 | -$0.33 | +25.00% | — | — |
| Q2 2023 May 12, 2023 | $160.00K | $410.00K | +156.25% | -$0.36 | -$0.44 | -22.22% | — | — |
| Q1 2023 Mar 29, 2023 | $150.00K | $11.00K | -92.67% | -$0.42 | -$0.36 | +14.29% | — | — |
| Q4 2022 Nov 8, 2022 | $101.75K | $359.00K | +252.83% | -$0.42 | -$0.40 | +4.76% | — | — |
| Q3 2022 Aug 9, 2022 | $1.43M | $407.00K | -71.63% | -$0.34 | -$0.43 | -26.47% | — | — |
| Q2 2022 May 10, 2022 | $2.68M | $5.37M | +100.00% | -$0.92 | -$0.54 | +41.30% | — | — |
| Q1 2022 Mar 9, 2022 | $1.13M | $271.00K | -75.91% | -$0.82 | -$1.05 | -28.05% | — | — |
| Q4 2021 Nov 9, 2021 | $400.00K | $14.00K | -96.50% | -$0.78 | -$0.85 | -8.97% | — | — |
| Q3 2021 Aug 9, 2021 | — | — | — | -$0.61 | -$0.85 | -39.34% | — | — |
| Q2 2021 May 11, 2021 | — | — | — | -$0.48 | -$0.60 | -25.00% | — | — |